Goodland Pharma was founded on the belief that successful recruitment is about more than just filling roles. We are partners invested in your long-term growth and achievement, offering seasoned expertise that delves deep into your world. Together, we can redefine the recruitment experience and unlock the full potential of your life science endeavours. Want to learn more? The contact details for Ryan Goodland will be in the comments!! #PartnershipApproach #ValueAddedServices #StrategicAdvising #IndustryInsights #RedefiningRecruitment
Goodland Pharma
Staffing and Recruiting
Your Vision. Our Expertise. One Partnership. Global Life Science recruitment.
About us
Goodland Pharma was created to offer a fresh perspective on global life science recruitment. Our Founder, Ryan Goodland, brings a proven track record of results, having placed global talent across 65 countries that contributed to over 10 FDA-approved drugs. Our mission is to establish trust-based partnerships, providing precise and targeted Life Science recruitment, delivered through industry-leading expertise and connecting our customers to the very best global talent Our vision is to be the trusted advisor of choice, redefining Life Science recruitment through class-leading specialist knowledge, mature and global connection portfolio and honest partnerships.
- Website
-
www.goodlandpharma.com
External link for Goodland Pharma
- Industry
- Staffing and Recruiting
- Company size
- 2-10 employees
- Headquarters
- New York
- Type
- Privately Held
- Founded
- 2024
Locations
-
Primary
New York, US
-
St. Albans, Hertfordshire AL1 5BU, GB
Employees at Goodland Pharma
Updates
-
How can life science companies responsibly leverage AI amid evolving regulations? The rapid advancement of AI presents both opportunities and risks for UK life science firms. From regulatory guidance on diagnostic devices to data security in clinical trials, companies must navigate complex challenges. Careful consideration of bias, transparency, and IP protection is crucial. By staying attuned to these key impacts, life science leaders can harness the power of AI while mitigating emerging liabilities. Get full details from the article here: https://bit.ly/4bnDyIL #AIinLifeSciences #UKHealthtech #DataSecurity #ProductLiability #Regulation
-
-
At Goodland Pharma, we don't just talk the talk - we walk the walk. With a proven track record of delivering exceptional results, our team has placed global talent across 65 countries. Partner with us and experience the difference that true expertise and commitment can make. Let us partner with you today: https://bit.ly/4b8osr1 #TrackRecordOfExcellence #DrugsApproved #GlobalRecruitmentSuccess #LifeSciencesAchievements #OutstandingResults
-
-
Vutrisiran - The future of ATTR-CM treatment? Alnylam has reported positive results from its closely watched HELIOS-B trial, showing that its experimental drug vutrisiran significantly reduced the risk of death and cardiovascular events in patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM). The findings could pave the way for vutrisiran to become a blockbuster treatment option in this indication. Read the exciting development here: https://bit.ly/3VLSWZG #Alnylam #ATTR-CM #CardiologyNews #DrugDevelopment #RNAi
-
-
Goodland Pharma was created with a vision that extends far beyond merely placing candidates. Our founder, Ryan Goodland, is driven by the thrill of contributing to groundbreaking scientific achievements, having placed talent that has led to over a dozen FDA-approved drugs. Partner with us and be a part of the journey towards advancing medicine and improving patient lives: https://bit.ly/4d6R9Xb #AdvancingMedicine #ImprovingPatientLives #GroundbreakingScience #LegacyOfSuccess #TransformativeRecruitment
-
-
Could Wave's Huntington's drug gain accelerated approval after promising trial results? Wave Life Sciences has unveiled new data from a placebo-controlled trial of its experimental Huntington's disease drug WVE-003. The results showed the therapy significantly lowered levels of the mutant “huntington” protein while preserving the wild-type form, leading the company to pursue discussions with regulators about a potential accelerated approval. Get the full details of the trial in this article: https://bit.ly/4bo9j4B #HuntingtonsDisease #DrugDevelopment #NewData #RegulatoryClearance #BiotechBreakthrough
-
-
We believe personalisation is not just a feature - it's the foundation of how we work. Our founder, Ryan Goodland, is committed to building genuine, trust-based relationships that go beyond traditional recruitment. We are committed to invest ourselves in your culture and needs, redefining the partnership experience. Get started with Goodland Pharma today: https://bit.ly/3IX7TlK #PersonalisedRecruitment #TrustBasedRelationships #CandidateExperience #CustomisedService
-
-
Repeat doses as the next frontier for CRISPR Therapies? Intellia Therapeutics, Inc. has presented first-of-its-kind data suggesting their CRISPR-based medicine could be given to patients more than once. The findings showed an additive effect when a second, higher dose was administered to three trial participants with transthyretin amyloidosis. This advance may enable tackling diseases requiring multiple CRISPR doses. Check out the exciting advancement here: https://bit.ly/4cI1ojM #Intellia #CRISPR #Amyloidosis #GeneTherapy #RedosingPotential
-
-
With a proven track record of placing talent that has contributed to over 10 FDA-approved drugs, our team at Goodland Pharma brings unparalleled expertise in the clinical trials landscape. We understand the nuances that drive success, helping you navigate the complexities to achieve your vision. Together, let’s take your life science projects to new heights. Get in touch with us today: https://bit.ly/4deeOVx #ClinicalTrialsExpertise #DrugApprovalProcess #MedicalResearch #FDAApproval #LifeSciencesSpecialists
-
-
Diseases do not exist in isolation - a wide range of social, economic and environmental factors influence their prevalence and outcomes. By applying a systems thinking approach, clinical trial design can better reflect this holistic perspective. Involving diverse stakeholders, prioritising participant needs and preferences, and considering sustainability are key to creating more flexible, efficient and human-centric trials. This can improve recruitment, retention and the overall value for all involved. Read the insightful article here: https://bit.ly/3zn3FT0 #ClinicalTrials #SystemsThinking #PatientCentricity #HumanCentric #SustainableResearch
-